Delivering better trial outcomes together
Why partner with Emeritus?
With over 25 years’ experience supporting biotech and pharma, Emeritus delivers Phase I–IV clinical trials from purpose-built sites in Melbourne and Sydney. We combine experienced investigators with a disciplined approach and high quality, rapid data turnaround.
Proven capability and trusted delivery
Trusted by sponsors for over 25 years
Phase I–IV outpatient trial capability
Sites in Melbourne and Sydney
Scalable recruitment expertise available
Trusted by
Why choose Australia for your clinical trial?
Australia offers a highly attractive environment for clinical research, combining efficient start-up pathways, rapid ethics and regulatory approvals, and strong clinical governance.
Clinical trial data generated in Australia is globally recognised by major regulatory agencies, including the FDA, while access to diverse and engaged participant populations supports reliable recruitment and high-quality outcomes.
Eligible sponsors may access a 43.5% R&D tax offset in Australia, helping to significantly reduce overall trial costs.
With the right local partner, Emeritus can support sponsor to navigate the Australian market with confidence and maintain momentum from study start-up through to results.
What sets Emeritus apart
Emeritus provides sponsors with a clear, dependable pathway to run clinical trials in Australia. With established sites in Melbourne and Sydney and deep local expertise, we are built to handle high patient volumes and rapid recruitment at scale, helping sponsors deliver with confidence.
How Emeritus approaches recruitment
Recruitment is critical to trial success, and at Emeritus it is strengthened by our exclusive partnership with Clinibase, Australia’s largest full service clinical trial recruitment provider and a sister company.
Clinibase delivers large-scale, targeted digital campaigns designed to reach specific patient populations, with every lead carefully pre-screened before a clinic visit is booked. This ensures only well qualified participants progress into the study.
Working closely with sponsors from the outset, Emeritus and Clinibase tailor recruitment and pre-screening to each study, creating a seamless, sponsor aligned pathway from first contact to first visit.
See how Emeritus delivers
Women's Health - Chronic HPV Trial
Across just two sites in Melbourne and Sydney, Emeritus delivered 20% of global enrolment for a Phase Ib/II chronic Human Papillomavirus trial spanning 34 sites and 5 countries. A highly complex protocol involving multiple dosing regimens, treatment cycles and lifestyle modifications was executed with precision, underpinned by our custom CTMS and the expertise of our dedicated clinical team.
Large Scale Flu Vaccine Study
Tasked with boosting Southern Hemisphere enrolment for a large Phase III flu vaccine trial, Emeritus enrolled 530 participants across our Melbourne and Sydney facilities in just 15 business days, with a 5% screen failure rate.
GLP-1 Obesity Trial
Emeritus was the highest recruiting site globally for a complex GLP-1 obesity trial, outperforming sites across the USA with nearly 100 participants enrolled. Despite four treatment arms and a challenging eligibility framework, our teams delivered a 96% retention rate at 9 months and completed a sponsor audit with no major findings.
COVID/Flu Combination Vaccine Study
When a large-scale vaccine study pivoted its scope less than one week before initiation, Emeritus adapted immediately, enrolling 283 participants across three sites within just 6 business days, demonstrating operational agility sponsors depend on when timelines shift unexpectedly.
Male Pattern Baldness Trial
Emeritus became the first site globally to dose participants in this ongoing dermatology trial, with a dedicated specialist PI leading the study from initiation. With 20 participants enrolled and on track to meet the entire Australian recruitment target across our sites alone, this trial reflects the speed, expertise and commitment Emeritus brings to every study we undertake.
Atopic Dermatitis Trial
Against a backdrop of tightening PBS access reducing the eligible patient pool in Australia, Emeritus enrolled 18 participants against an original site target of 7 for a moderate-to-severe atopic dermatitis study, achieving full enrolment within 8 months through targeted recruitment and structured pre-screening.